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ABSTRACT
Telomeres are repeated nucleotide sequences that cap the ends of each chromosome in
eukaryotes. Telomeres are among the earliest genomic sequences to be degraded during
apoptosis, potentially providing a biomarker of cell death. To study this, we quantified
telomeres in serum from Glioblastoma and non-cancer patients. Cell-free DNA was
isolated by centrifugation to remove intact cells, and purified using a QIAamp DNA
Blood Midi Kit (Qiagen). Cell-free telomeric (cf-tel) and cell-free actin (cf-actin) DNA
were analyzed with quantitative PCR. Total cell-free DNA was measured with PicoGreen
assays. We hypothesize that patients with Glioblastoma tumors have higher cf-tel DNA
levels than those without tumors. Our results indicate that cf-tel DNA was present at
nearly double the amount in Glioblastoma patients when compared to non-cancer control
patients with a significant difference (p=0.0151), while cf-actin DNA and total cell-free
DNA amounts for Glioblastoma patients and non-cancer control patients were nearly
identical. We conclude that cell-free telomeric DNA can be detected and measured in
serum from normal patients and patients with a history of Glioblastoma, the increased
presence of cell-free telomeric DNA is directly correlated with Glioblastoma disease
conditions, and cell-free telomeric DNA may be a useful clinical biomarker for treatment
response and for measurement of tumor burden.
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1. INTRODUCTION
1.1 Glioblastoma
Glioblastoma (GBM) is the most frequent and malignant type of brain tumor.
Glioblastomas arise from astrocytes, a gel-like tissue that makes up the supportive tissue
of the brain and assumes multiple roles in maintaining an optimally suited environment
for neuronal function [1]. The vast majority of Glioblastoma cases, about 90%, are
categorized as primary Glioblastoma. Primary Glioblastomas develop de novo, or without
clinical or histologic evidence of a less malignant precursor lesion, in older patients with
a mean age of 62 years. They are genetically characterized by loss of heterozygosity on
chromosome 10q (70% of cases), epidermal growth factor receptor overexpression
(36%), p16INK4a tumor suppressor protein deletion (31%), and PTEN gene mutations
(25%). Secondary glioblastomas develop through progression from an original, lowgrade, non-localized astrocytoma or anaplastic astrocytoma, and manifest in younger
patients with a mean age of 45 years [2]. Secondary Glioblastomas are genetically
characterized most commonly by TP53 gene mutations, already present in 60% of
precursor low-grade astrocytomas. Primary Glioblastomas predominantly affect males,
with a population-based male to female ratio of 1.33:1, while secondary glioblastomas
primarily occur in females, with a population-based male to female ratio of 0.65:1.
Histological criteria for the diagnosis of Glioblastoma include: nuclear atypia, cellular
variation of size and shape, mitotic activity, vascular thrombosis, microvascular
proliferation, and necrosis [3]. The incidence rate of primary glioblastomas in the United
States is 2.96 new cases per 100,000 individuals per year, making it a more rare form of
cancer. [2] Glioblastoma symptoms are usually caused by increased pressure in the brain,
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necrosis of brain tissue, and seizures caused by the location of the tumor [18]. These
symptoms can include headache, nausea, vomiting, and drowsiness. Also, depending on
the location of the tumor, patients can develop a variety of other symptoms such as
weakness on one side of the body, memory or speech difficulties, and changes in sight
[4]. The most frequent location for Glioblastomas are in the cerebral hemispheres, with
95% of these tumors arising in the supratentorial region. Only a small percent of tumors
occur in the cerebellum, brainstem, and spinal cord [18]. Glioblastoma is very difficult to
treat due to its location and rapid progression. Treatment options include surgery to
remove tumor, as well as radiation and chemotherapy to slow the growth of tumors.
Prognosis of both primary and secondary Glioblastoma is generally very poor. The
majority of patients with primary Glioblastoma (68%) had a clinical history of less than 3
months, with a mean duration of first symptom to diagnosis of 6.3 months. The median
overall survival of patients clinically diagnosed with primary Glioblastoma is 4.7 months.
The mean duration of the clinical history of patients with secondary Glioblastoma was
16.8 months, with a median survival of 7.8 months, significantly longer due to the
younger age of patients diagnosed with secondary Glioblastoma. To date GBM remains
incurable due to its heterogeneity and complex pathogenesis. Continued research efforts
will help to provide better treatment options to combat the disease in the future [18].
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Figure 1: The above image shows four different patients with GBM that illustrate the
heterogeneity of the tumor: (a) rim-enhancing mass with central necrosis in the right
parietal lobe with surrounding edema; (b) irregularly enhancing mass that crosses the
corpus callosum; (c) well-circumscribed homogeneously enhancing mass in the left
frontal lobe with no associated edema; (d) ill-defined infiltrative mass in the left medial
frontal lobe with no noticeable necrosis [18].

3

1.2 Telomeres
Telomeres are sequences at the ends of eukaryotic chromosomes that help
stabilize the DNA. Telomeres consist of multiple repeated sequences of the form
5’TTAGGG3’ in humans, with repeats at the end of strands generally numbering more
the 1,500. Telomeres are characterized by a TG leading strand that is longer than its
complement, leaving an overhang region of single-stranded DNA of up to a few hundred
nucleotides at the 3’ end [5]. Telomeres are also coated by a capping protein complex
called shelterin. Three shelterin subunits, TRF1, TRF2, and POT1 directly recognize
telomeric repeats, and bind with three additional proteins, TIN2, TPP1, and Rap1, to form
a complex that allow cells to distinguish telomeres’ extended overhang region from sites
of double-stranded DNA damage. Without the protective activity of shelterin, telomeres
would be inappropriately processed by DNA repair pathways and leave the coding
regions of the DNA unprotected [6].
Telomeres protect against threats to the genome that arise from a difficulty
inherent in the asymmetric replication of DNA. The ends of linear eukaryotic DNA
cannot be routinely replicated by normal cellular replication machinery due to DNA
polymerase requiring an RNA primer with a 3′ hydroxyl donor group to initiate DNA
replication. Without telomeres, genetic material would be lost every time a cell divides.
Therefore, repeated telomeric sequences are added to eukaryotic chromosome ends
primarily by the enzyme telomerase [5]. Telomeres and telomerase alleviate this problem
by providing a repetitive protective template that can be repaired on the ends of
chromosomes, thereby avoiding the loss of genetically encoded information during
replication. Telomerase works by containing an RNA component, about 150 nucleotides
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long of the form 3’AAUCCC5’, that serves as a RNA template for the synthesis of the
repeated 5’TTAGGG3’ DNA strand of the telomere. Telomerase binds to the parental
single-stranded overhang and extends the parental strand with a 5’TTAGGG3’ DNA
repeat. Telomerase then repositions itself on the parental strand and continuously extends
this strand with multiple 5’TTAGGG3’ repeats. After the parental strand has been
significantly extended by multiple telomeric repeats, DNA primase adds a RNA primer
near the 3’ end and DNA polymerase fills in the vacant region of the telomere. A short
overhang on the parental strand will remain; however, the end result is that telomerase
will have added many repeat sequences from a few dozen to a few hundred, preventing
chromosome ends or coding regions of DNA from shortening.
Efforts to uncover the underlying mechanisms driving genome instability in
cancer have revealed a prominent role for telomeres [7]. With subsequent DNA
replications in normal cells, telomeric ends continually shorten. As telomere erosion
continues, the loss of telomere capping functions produces rampant chromosomal
instability and widespread apoptosis. Similarly, shorter telomeres, caused by normal
aging, can also induce genomic instability and may contribute to the development of
some cancers [8]. Telomerase is used to replicate telomeres and prevent degradation. Yet,
despite standard telomerase function, normal cells are still programed to eventually
expire. However, in some cancer cells, telomere length is continuously maintained
despite multiple cellular divisions due to the overexpression of telomerase reverse
transcriptase (TERT), the catalytic protein subunit of telomerase. The ability of
telomerase to endow normal cells, which are destined to age and die, with immortal
growth potential by preventing the shortening of telomeres has provoked widespread
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speculation that telomerase reactivation plays a role in human cancer development.
Furthermore, DNA damage-induced apoptosis, which is caused by cell trauma due to
conditions like cancer, results in a dramatic telomere loss. It has been shown that cells
undergoing apoptosis upon DNA damage also exhibit a rapid and dramatic loss of
telomeric sequences [9].
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Figure 2: (Top) In normal organisms, groups of stem cells (blue, rounded cells)
called niches repair tissues. The stem cells exit the niche, proliferate, and differentiate
(square, orange cells). (Bottom left) In older organisms, stem cells have insufficient
telomerase activity to maintain telomere integrity. Stem cell telomeres are too short, and
consequently tissue regeneration is suboptimal. The ultimate consequence of impaired
cell mobilization will be organ failure due to tissue degeneration. (Bottom right) If stem
cells express high levels of telomerase, stem cells mobilize more efficiently than normal.
Under these conditions, tissues would be maintained longer, therefore increasing life
span. However, the probability of forming a tumor is higher [17].
7

1.3 Cell-Free DNA
Cell-free DNA (or cfDNA) refers to all non-encapsulated DNA in the blood
stream [10]. The release of nucleic acids into the blood is related to the apoptosis and
necrosis of cells, including that of cancer cells in the tumor microenvironment.
Fragments of cellular nucleic acids can also be actively released. It has been estimated
that for a patient with a tumor that weighs 100 g, which corresponds to 30 billion tumor
cells, up to 3.3% of that tumor’s DNA may enter the blood every day. The size of this
cell-free DNA varies between small fragments of 70 to 200 base pairs and large
fragments of approximately 21 kilobases. Nucleic acids are cleared from the blood by the
liver and kidney, and they have a variable life in circulation ranging from 15 minutes to
several hours [11].
Tumor cells that circulate in the blood and metastatic deposits that are present at
distant sites can further contribute to the release of cfDNA. Increased levels of circulating
nucleic acids (DNA, mRNA and microRNA (miRNA)) in the blood reflect pathological
processes, including malignant and benign lesions, inflammatory diseases, stroke, trauma
and sepsis. In cancer patients, circulating DNA carries tumor-related genetic and
epigenetic alterations that are relevant to cancer development, progression and resistance
to therapy. The cellular source of tumor-derived circulating nucleic acids is still subject to
debate. After complete removal of the primary tumor, the detection of cfDNA may signal
the presence of micrometastatic cells in distant organs, which pose a risk of relapse.
Minimally invasive blood analyses of cell-free DNA allow repetitive, real-time
monitoring of metastatic changes and will, therefore, gain clinical utility in the
determination of prognosis and treatment efficacy. Cell-free DNA in plasma or serum has
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the clinical potential to become a more specific tumor marker for the diagnosis and
prognosis, as well as the early detection, of cancer [11]. Measuring cell-free DNA may
complement currently used tumor markers for the management of cancer patients. Cellfree DNA has been described as a viable biomarker of several cancers across multiple
studies [12,13,14,15]. Circulating tumor DNA is an informative, inherently specific, and
highly sensitive biomarker of metastatic cancer [20].
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2. METHODS
2.1 Patient Samples
This research was conducted at the headquarters of Blondin Bioscience in
Birmingham, AL under the direct supervision of Dr. Katri Selander, Dr. Kevin Harris,
Mr. Brad Spencer, and Mr. Kevin Stoltz. Fifty patient samples, provided by the
University of Alabama-Birmingham, were used for this study. Forty samples contained
the serum collected from blood samples of various patients across different stages of
primary Glioblastoma. Nine samples contained the serum collected from blood samples
of various non-cancer patients with Epilepsy. Samples were collected between 2008 and
2015, and were immediately frozen until used to prevent DNA degradation. The identity,
clinical information, and outcome of these patients were unknown due to HIPAA laws.

2.2 DNA Isolation
The 1000-µL serum samples were centrifuged at 13000 rpm for 5 minutes in a
microcentrifuge at room temperature to remove cells and large cellular debris. 500 µL of
the supernatant liquid was carefully removed from each sample, and the supernatant
liquid was centrifuged again in a microcentrifuge at 13,000 rpm for 5 minutes at room
temperature to further remove cellular debris. 400 µL of the supernatant liquid from the
second centrifugation was removed and frozen until time for DNA isolation. DNA
isolation of the cell-free samples was done with a QIAamp DNA Blood Midi Kit
(Qiagen) using the following standard protocol. 40 µL Qiagen Protease was added to a
clean 1.5 mL microcentrifuge tube. 400 µL of serum sample was added to the tube. 400
µL of AL buffer was added to the tube, and the tube was pulse vortexed for 15 seconds to

10

lyse the cells. After pulse vortex, the mixture was incubated for 10 minutes at 56 °C to
achieve the maximum DNA yield. Next, 400 µL of ethanol (96-100%) was added, and
the tube was pulse vortexed again for 15 seconds. 500 µL of the subsequent mixture was
added to a Midi Spin Column, and spun in a microcentrifuge at 13000 rpm for 1 minute.
The contents collected in the collection tube were discarded. Afterwards, the Midi Spin
Column was re-spun at 13000 rpm for 1 minute, and collection tube contents were
discarded again to further remove any unwanted contaminates. Next, 750 µL of wash
buffer AW1 was added to the Midi Spin Column, and spun in a microcentrifuge at 13000
rpm for 1 minute. The contents collected in the collection tube were discarded.
Afterwards, the Midi Spin Column was re-spun at 13000 rpm for 1 minute, and collection
tube contents were discarded again to further remove any unwanted contaminates. This
process was repeated exactly for wash buffer AW2. Afterwards, the Midi Spin Column
was spun once again at 13000 rpm for 1 minute to dry the membrane, and the collection
tube was discarded. Lastly, the Midi Spin Column was placed on a clean 1.5 mL
microcentrifuge tube. 400 µL of elution buffer AE was added to the column, and allowed
to incubate for 1 minute at room temperature. The column was then spun at 8000 rpm for
1 minute and the isolated DNA was collected in the 1.5 mL tube.

2.3 Quantitative PCR
Cell-free telomeric DNA was measured using Cawthon Quantitative PCR [16]. A
nine step, 4x serial dilution DNA standard curve ranging from 1500-0.02 ng/mL created
using human genomic DNA was used for this assay. A specific combination, or cocktail,
of DNA, either standard curve or experimental, nuclease-free DI water, forward and
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reverse qPCR primers, and 2x All-in-One qPCR mastermix was plated in triplicate for
each unknown DNA sample in a 96-well plate. Thermal cycling conditions for cf-tel
DNA were 2 min at 50 °C, 10 min at 95 °C, 26 cycles of 15 sec at 96 °C and 2 min at 54
°C, 2 min at 95 °C, 2 min at 50 °C, 15 sec at 95 °C, 15 sec at 60 °C, and 15 sec at 95 °C.
Thermal cycling conditions for cf-actin DNA were 2 min at 50 °C, 10 min at 95 °C, 40
cycles of 15 sec at 96 °C and 1 min at 60 °C, 2 min at 95 °C, 2 min at 50 °C, 15 sec at 95
°C, 15 sec at 60 °C, and 15 sec at 95 °C. The use of normal genomic DNA for a standard
curve allowed us to directly determine relative cf-tel and cf-actin DNA concentrations in
the test samples.

2.4 PicoGreen Analysis
Total cell-free DNA was measured using a Quant-iT PicoGreen fluorescent assay.
A 4-step, 10x serial dilution DNA standard curve ranging from 1000-1 ng/mL created
using lambda DNA was used for this assay. A specific combination of DNA, either
standard curve or experimental, and PicoGreen reagent, composed of Quant-iT
PicoGreen dsDNA reagent and TE buffer, was plated into a 96-well microplate. A Cary
eclipse fluorescence spectrophotometer measured the absorbance of each DNA sample.
Samples were excited at a wavelength of 480 nm and emissions were measured at a
wavelength of 520 nm. Once all absorbance values were measured, concentrations were
determined based off of a graph of the standard curve’s absorbance vs. concentration
shown in Figure 3.
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Standard Curve Absorbance vs.
Concentration
700
y = 0.5474x + 30.523
R² = 0.99989

Absorbance

600
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400
300
200
100
0
0

200
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Figure 3: Graph of Absorbance vs. Concentration based on the standard curve created to
determine the total DNA concentrations of each unknown sample. Our y-intercept for this
graph ideally should be 0, as our blank should not have fluoresced. However, our
absorbance reading for our blank measured 32.332, explaining the cause of our raised yintercept. Another issue concerning the accuracy of our results is that the majority of our
calculated total cell-free DNA concentrations fall within the lower range of our standard
curve. One way to improve the accuracy of this test would be to adjust the standard curve
by only measuring the absorbance of multiple lower concentrations of lambda DNA to
more accurately analyze lower end total cell-free DNA concentrations.
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2.5 Statistical Procedure
PRISM 7 (GraphPad) was used to conduct all statistical analyses. Standard error
of measurement was determined. Unpaired t-tests were used to determine statistical
significance at a level of P<0.05. A p-value of 0.05 signifies that there is only a 5%
chance that the values analyzed are different due to mere random chance, strongly
suggesting that there is some other mechanism responsible for the difference between the
two groups. Due to a wide range in our results, some data points were excluded from
statistical analysis as outliers. The criteria for selecting these outliers was if the value of
the data point was at least 10-fold greater than other values of the same category the data
point was considered an outlier. For this set of experiments we found and excluded four
outliers.
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3. RESULTS
3.1 Summary of Results
Our experiments focused on successfully quantifying the amount of cell-free
telomeric DNA in cancer patients. We hypothesized that a) cell-free telomeric DNA is
released in significantly higher amounts in patients with Glioblastoma than non-cancer
control patients, b) other cell-free DNA measurements would not have significant
differences between cancer and non-cancer patients, c) cell-free telomeric DNA would be
preferentially released in cancer patients compared to other cell-free DNA microparticles
(cf-actin). Table 1 summarizes the result from this research.

3.2 Cell-free telomere DNA
To determine if cell-free telomeric DNA is released in significantly higher
amounts in Glioblastoma patients, we used qPCR to quantify the amount of cf-tel DNA
released by 40 Glioblastoma patients and compared it to the amount of cf-tel DNA
released by 9 non-cancer patients. Each sample was run in triplicate to ensure accurate
readings and to decrease the possibility of human error. Detectable amounts of cf-tel
DNA were measured in both sets of patients. An outlier in sample 3 of the control group,
which measured a cf-tel DNA mean amount over 30-fold greater than the other samples,
was noticed and removed before statistical analysis. After collecting data, we determined
the mean level of cf-tel DNA in Glioblastoma patents to be 2.063-ng/mL ± 0.1526, and
the mean level of cf-tel in non-cancer patients to be 1.185-ng/mL ± 0.1167, a nearly 2fold increase in difference between Glioblastoma and non-cancer patients. We
subsequently ran a two-tailed, unpaired t-test on the mean levels of cf-tel DNA, and
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Table 1: Summary of the results of qPCR and PicoGreen Analysis. All concentrations
are measured by ng/mL. Each sample is representative of a single patient either in the
control or Glioblastoma group. Concentrations of cf-tel and cf-actin DNA are averages of
measurements made in triplicate.
Sample
C1
C2
C3
C4
C5
C6
C7
C8
C9
GBM1
GBM2
GBM3
GBM4
GBM5
GBM6
GBM7
GBM8
GBM9
GBM10
GBM11
GBM12
GBM13
GBM14
GBM15
GBM16
GBM17
GBM18
GBM19
GBM20
GBM21
GBM22
GBM23
GBM24
GBM25
GBM26
GBM27
GBM28
GBM29
GBM30
GBM31
GBM32
GBM33
GBM34
GBM35
GBM36
GBM37
GBM38
GBM39
GBM40

Average cf-tel DNA
1.44
1.24
30.87
1.25
1.08
1.81
0.98
0.82
0.85
1.73
1.04
2.22
1.40
0.57
5.27
1.32
1.77
2.01
2.81
1.63
3.38
0.60
1.17
3.02
2.99
3.41
2.22
3.02
2.43
2.01
1.72
1.63
1.81
1.75
3.27
2.75
1.75
1.31
1.08
1.20
2.57
1.82
1.38
2.15
2.19
2.95
0.83
3.49
0.81

Average cf-actin DNA
2.43
1.98
14.29
1.44
2.12
1.26
1.80
1.38
1.54
1.78
1.62
2.35
1.64
1.68
16.73
1.87
2.36
1.44
2.58
2.35
2.39
1.11
0.84
3.06
1.32
2.30
1.11
0.89
1.07
1.49
1.98
0.80
1.09
0.64
5.36
4.19
0.79
0.82
1.04
0.93
0.55
1.60
1.61
0.58
0.78
4.20
1.05
0.71
1.13
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Total cell-free DNA
43.04
41.32
557.33
35.44
50.9
50.97
43.55
68.98
100.09
44.15
51.32
49.84
46.2
49.45
134.02
45.51
80.38
69.82
58.64
49.51
76.11
43.06
52.96
68.29
44.56
52.16
59.12
49.47
43.41
56.56
45.73
66.19
56.05
40.3
59.68
65.35
51.79
55.37
53.65
67.63
65.07
59.92
52.59
61.2
51.32
57.07
44.94
36.54
40.08

achieved significant results (p=0.0151), signifying that the difference between cf-tel
DNA levels between cancer and non-cancer patients was not due to chance. This supports
our hypothesis that cell-free telomeric DNA is released in significantly higher amounts in
patients with Glioblastoma than non-cancer control patients, making it a viable biomarker
for assessment of Glioblastoma patients. The measurements of cf-tel DNA for each
sample and differences between Glioblastoma and non-cancer patient’s levels are shown
below in Figure 4.
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Figure 4: Cell-free telomeric DNA is detectable in both Glioblastoma and non-cancer
patents. Results are expressed as total relative telomere amounts as calculated from a
normal human genomic DNA standard curve. Bars indicate the mean value of each
group, 2.063-ng/mL for GBM and 1.185-ng/mL for Control. There was a significant
difference between the mean value for the GBM group and the control group (p=0.0151).
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3.3 Cell-free actin and total cell-free DNA
Next, to determine if other cell-free DNA measurements were significantly
different between cancer and non-cancer patients, we used qPCR and PicoGreen analysis
to quantify the amount of cell-free actin DNA and total cell-free DNA, respectively, in
the same 40 Glioblastoma and 9 non-cancer control patients. For the cf-actin qPCR, each
sample was run in triplicate to ensure accurate readings and to decrease the possibility of
human error. For total cell-free DNA PicoGreen analysis, each sample was run once.
Detectable amounts of cf-actin and total DNA were measured in both sets of patients.
Three outliers were noticed and removed before statistical analysis. Two of the outliers
were the measurements for control sample 3 of both cf-actin and total cell-free DNA,
which measured a cf-actin DNA mean amount about 13-fold greater and a total cell-free
DNA mean amount about 10-fold greater than the other respective samples. The other
outlier was the measurement for Glioblastoma sample 6 of cf-actin, which measured a cfactin DNA mean amount about 15-fold greater than the other respective samples. After
collecting data, we determined the mean level of cf-actin DNA in Glioblastoma patents to
be 1.67-ng/mL ± 0.1713, and the mean level of cf-actin in non-cancer patients to be
1.743-ng/mL ± 0.144. We determined the mean level of total cell-free DNA in
Glioblastoma patents to be 56.38-ng/mL ± 2.542, and the mean level of total cell-free
DNA in non-cancer patients to be 54.29-ng/mL ± 7.442. We subsequently ran a twotailed, unpaired t-test on the mean levels of cf-actin DNA and total cell-free DNA, and
did not achieve significant results for either (p=0.8504 for cf-actin DNA and p=0.7515
for total cell-free DNA), signifying that the difference between both cf-actin DNA levels
and total cell-free DNA levels between Glioblastoma and non-cancer patients was due to
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chance. This supports our hypothesis that other cell-free DNA measurements, cf-actin
and total cell-free DNA, would not have significant differences between cancer and noncancer patients, making cf-tel DNA a unique biomarker for the measurement of tumor
burden and treatment response. The measurements of cf-actin DNA for each sample, and
differences between Glioblastoma and non-cancer patient’s levels, are shown below in
Figure 5. The measurements of total cell-free DNA for each sample, and differences
between Glioblastoma and non-cancer patient’s levels, are shown below in Figure 6.
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Figure 5: Cell-free actin DNA is detectable in both Glioblastoma and non-cancer patents.
Results are expressed as total relative telomere amounts as calculated from a normal
human genomic DNA standard curve. Bars indicate the mean value of each group, 1.67ng/mL for GBM and 1.743-ng/mL for Control. There was no significant difference
between the mean value for the GBM group and the control group (p=0.8504)
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Figure 6: Total cell-free DNA is detectable in both Glioblastoma and non-cancer patents.
Results are expressed as total relative telomere amounts as calculated from a lambda
DNA standard curve. Bars indicate the mean value of each group, 56.38-ng/mL for GBM
and 54.29-ng/mL for Control. There was no significant difference between the mean
value for the GBM group and the control group (p=0.7515)
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3.4 Comparison of cf-tel and cf-actin
Lastly, to determine if cell-free telomeric DNA would be preferentially released
in the Glioblastoma microenvironment compared to other cell-free DNA microparticles
(cf-actin), we compared the results of cf-tel and cf-actin qPCR to determine which
microparticle was released in higher amounts for Glioblastoma patients. An outlier for cfactin in Glioblastoma sample 6, which measured a cf-actin DNA mean amount about 15fold greater than the other samples, was noticed and removed before statistical analysis.
After analyzing data, we determined the mean level of cf-tel DNA in Glioblastoma
patents to be 2.063-ng/mL ± 0.1526, and the mean level of cf-actin in Glioblastoma
patients to be 1.67-ng/mL ± 0.1713. We subsequently ran a two-tailed, unpaired t-test on
the mean levels of cf-tel DNA vs. cf-actin DNA in Glioblastoma patients, and
unfortunately did not achieve significant results (p=0.0903), signifying that the difference
between cf-tel DNA levels and cf-actin DNA levels in Glioblastoma patients was due to
chance under our set of parameters. However, if the alpha level of our test is changed
from α=0.05 to α=0.1, the test is changed to a one-tailed t-test (p=0.0452), or if a few
data points are removed from analysis, results become significant. Also, the prevalence of
cf-tel DNA over cf-actin DNA in Glioblastoma patients is further suggested when these
results are compared to the results for the non-cancer control group, where cf-actin DNA
is present in significantly higher amounts than cf-tel DNA (p=0.0093), signifying that the
difference between cf-tel DNA levels and cf-actin DNA levels in non-cancer patients are
not due to chance. However, these results should not be trusted due to the small sample
size (n=8). Overall, this indicates that if additional subjects were added to the study, a
more definitive conclusion could be drawn. Had significant results been found, they
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would have supported our hypothesis that cell-free telomeric DNA would be
preferentially released in cancer patients compared to other cell-free DNA microparticles.
The measurements of cf-tel DNA and cf-actin DNA for each sample and differences
between cf-tel DNA and cf-actin DNA in Glioblastoma patient’s levels are shown below
in Figure 7. The measurements of cf-tel DNA and cf-actin DNA for each sample and
differences between cf-tel DNA and cf-actin DNA in non-cancer control patient’s levels
are shown below in Figure 8.
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Figure 7: Cell-free telomeric and cell-free actin DNA is detectable in Glioblastoma
patents. Results are expressed as total relative telomere amounts as calculated from a
normal human genomic DNA standard curve. Bars indicate the mean value of each
group, 2.063-ng/mL for cf-tel and 1.67-ng/mL for cf-actin. There was no significant
difference between the mean value for the cf-tel GBM group and the cf-actin GBM group
(p=0.0.0903)
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cf-tel vs. cf-actin Control
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Figure 8: Cell-free telomeric and cell-free actin DNA is detectable in non-cancer patents.
Results are expressed as total relative telomere amounts as calculated from a normal
human genomic DNA standard curve. Bars indicate the mean value of each group, 1.185ng/mL for cf-tel and 1.743-ng/mL for cf-actin. There was a significant difference
between the mean value for the cf-tel Control group and the cf-actin Control group
(p=0.0.0093)
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4. DISCUSSION
Our project aimed to be a preliminary study to determine the likelihood and show
evidence of measurable cf-tel DNA in Glioblastoma patient blood serum. We
hypothesized that a) cell-free telomeric DNA is released in significantly higher amounts
in patients with Glioblastoma than non-cancer control patients, b) other cell-free DNA
measurements would not have significant differences between cancer and non-cancer
patients, and c) cell-free telomeric DNA would be preferentially released in cancer
patients compared to other cell-free DNA microparticles (cf-actin). These hypotheses
point towards the idea that cf-tel DNA could be an effective and unique biomarker for
treatment response and tumor burden in Glioblastoma patients. We predict that plasma
cf-tel DNA levels will decrease with time during effective cancer treatment, but will not
decrease with time during ineffective cancer treatment. We predict that plasma cf-tel
DNA levels also surge upon tumor evolution or metastasis, treatment-resistant clones
emerging, and in the case of cancer relapse. Lastly, within the clinical setting, measuring
cf-tel DNA would enable oncologists to rapidly assess chemotherapy regimens for
patients, getting them to the optimum treatment pathway sooner and in a more costeffective manner than traditional tumor size imaging.
In our project, we show that telomeric DNA can be detected and quantified in the
serum of cancer patients and healthy individuals. We also discovered that cf-tel DNA was
present in significantly greater amounts in the serum of Glioblastoma patients compared
to that of non-cancer patients, suggesting that cf-tel DNA is released in measurably
higher amounts in Glioblastoma patients than non-cancer patients due to the disease
conditions. This finding was not similar for cf-actin or total cell-free DNA. Due to the
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inability to replicate the findings of cf-tel DNA in cf-actin or total cell-free DNA, we can
conclude that cf-tel DNA could be a unique biomarker for the measurement of tumor
burden and treatment response in Glioblastoma patients, as other cell-free DNA
measurements were unable to detect significant difference between Glioblastoma and
non-cancer environments.
One possible mechanism for the preferential release of cf-tel DNA is increased
apoptosis-mediated DNA degradation of the telomere region in particular compared to
other genomic regions. As stated in the introduction, DNA damage-induced apoptosis
caused by cell trauma due to conditions like cancer results in a dramatic telomere loss [9].
Furthermore, the apoptosis and necrosis of cells are related to the release of nucleic acids
into the blood [11]. Therefore, Glioblastoma mediated apoptosis and necrosis of cells
would lead to the preferential release of telomeric DNA into the blood, causing the
measurably elevated levels of cf-tel DNA in Glioblastoma patients.
There was a seemingly large range of values in both Glioblastoma and non-cancer
patients. We suspect that this indicates variations in normal activities during daily life,
and potentially changes in the pathology of the disease. Nucleic acids are cleared from
the blood by the liver and kidney, and they have a variable half-life in the circulation
ranging from 15 minutes to several hours [11]. Therefore, even in healthy, non-cancer
individuals it is possible to have spikes in cf-tel DNA release caused by DNA damage
due to normal activities such as minor injuries or acute illness, making the timing of the
collection of samples very important. This proved true for our data, as the ranges in
values of cf-tel DNA in non-cancer patients included a few outliers that could have been
caused by acute cellular trauma. However, if this is the case, changes in pathology such
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as tumor evolution, treatment-resistant clones emerging, and cancer relapse could
increase the amount of cf-tel DNA in plasma. This variation also proved true for our
study, as the range in cf-tel measurements for the Glioblastoma patients could have been
caused by patients at different stages of tumor development and treatment. A potential
future study could compare the values of cf-tel DNA to patient staging information and
determine if higher levels of cf-tel correlated to more aggressive and developed
Glioblastoma tumors as we have predicted. This was not possible in our study as patient
information was withheld from researchers. Other potential future studies could include
cell culture and animal model experiments to visualize the effects of different
chemotherapy regiments on the release of cf-tel DNA.
Practicing oncologists and professional clinical societies are currently
emphasizing the need for improved biomarkers for cancer treatment monitoring. Tumor
biopsies have been and currently are the keystone for biomarker testing. However, some
limitations of tumor biopsies are still significant, such as difficulties in obtaining tissue
samples, and the invasiveness of the process [19]. Glioblastoma is an extremely rapidly
progressing form of cancer that is located in a difficult region to biopsy. Glioblastoma is
treated by surgery to remove tumor, as well as radiation and chemotherapy to slow the
growth of tumors. Because the disease progresses rapidly, accuracy and efficiency in the
development of a treatment plan are crucial to the outcome of the patient. Taken together,
this suggests that there is a need for rapid, inexpensive, cell-free blood biomarker that can
help quickly determine if a specific chemotherapy regimen is working, and to detect the
presence of metastatic deposits that are present at distant sites. This would enable the
clinician to limit exposure to ineffective regimens and decrease side effects, cost, and
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wasted time for the patient. It also would confirm the complete removal of tumors, and
alert physicians to further actions that may need to be taken elsewhere in the body. The
measurement of serum cf-tel DNA during chemotherapy treatment and after surgery may
aid this decision-making process. Further studies of cf-tel DNA could lead to the
development of a unique cancer biomarker for cell death in vivo. A rise in cf-tel DNA
could be an omen for early relapse, thus allowing this to be a sensitive minimal residual
disease marker for diagnosis in the future.
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5. CONCLUSIONS
This thesis project had the goal of quantifying the concentrations of telomeres in
serum from Glioblastoma and non-cancer patients. Our results indicated that cf-tel DNA
was present at nearly double the amount in Glioblastoma patients when compared to noncancer control patients with a significant difference (p=0.0151), while cf-actin DNA and
total cell-free DNA amounts for Glioblastoma patients and non-cancer control patients
were nearly identical. This suggests that cell-free telomeric DNA can be detected and
measured in serum from normal patients and patients with a history of Glioblastoma, and
that the increased presence of cell-free telomeric DNA can be directly correlated with
Glioblastoma disease conditions. We can infer from these results that cell-free telomeric
DNA may be useful as a clinical biomarker for treatment response and for measurement
of tumor burden. This research should result in a publication within the next few years.
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